A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study
一项针对处于第二次或第三次完全缓解期的上皮性卵巢癌、输卵管癌或腹膜癌患者的II期随机、双盲试验，比较多价疫苗-KLH偶联物（NSC 748933 IND# 14384）+ OPT-821与单用OPT-821的疗效：NRG Oncology/GOG研究
期刊:Gynecologic Oncology
影响因子:4.1
doi:10.1016/j.ygyno.2019.09.015
O'Cearbhaill, Roisin E; Deng, Wei; Chen, Lee-May; Lucci, Joseph A 3rd; Behbakht, Kian; Spirtos, Nick M; Muller, Carolyn Y; Benigno, Benedict B; Powell, Matthew A; Berry, Emily; Tewari, Krishnansu S; Hanjani, Parviz; Lankes, Heather A; Aghajanian, Carol; Sabbatini, Paul J
